Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

7. maj 2026 opdateret af: Florida Atlantic University
The purpose of this study is to assess the feasibility of a 4-week intervention combining exercise and transcranial alternating current stimulation (Ex+tACS) in breast cancer survivors who report experiencing cancer-related cognitive impairment. Feasibility will be assessed by measuring participant retention, adherence, satisfaction with the intervention, and safety. The researchers will also examine pre-to-post intervention changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).

Studieoversigt

Detaljeret beskrivelse

Breast cancer is one of the most common forms of cancer among women in the United States. Although advances in cancer treatments have led to improved survival rates, breast cancer survivors must contend with the negative side effects from the cancer and its treatments. One of the most common and highly distressing treatment side effects is cancer-related cognitive impairment (CRCI), which is characterized by losses in memory, attention, processing speed, and executive function, which make daily tasks such as recalling information, organizing daily routines, concentrating, and multitasking more challenging. Findings from previous studies support aerobic exercise training as an effective strategy for improving cognitive function. In addition, non-invasive brain stimulation (NIBS), a technique in which electrodes are applied to the skin to noninvasively stimulate specific regions of the brain, has also been found to be a safe and effective approach for improving cognitive outcomes. Among various NIBS techniques, transcranial alternating current stimulation (tACS), which delivers current to the brain in an alternating pattern, may be a promising strategy for improving cognitive outcomes. Few studies have explored these approaches in breast cancer survivors, and to our knowledge, the combination of exercise and tACS (Ex+tACS) has not been explored.

This study will assess the feasibility of a 4-week Ex+tACS intervention in breast cancer survivors who report cancer-related cognitive impairment. Researchers will also examine changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Ashley L Artese, PhD
  • Telefonnummer: 856-534-8926
  • E-mail: aartese@fau.edu

Studiesteder

    • Florida
      • Boca Raton, Florida, Forenede Stater, 33431
        • Rekruttering
        • Florida Atlantic University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Breast cancer survivors (≥18 years) will be eligible to participate if the following inclusion criteria is met:
  • Diagnosed non-metastatic breast cancer (stages 0-3)
  • Completed primary breast cancer treatment (surgery, chemotherapy, radiation) for at least 3 months
  • Self-reported cognitive impairment after cancer treatment

Exclusion Criteria:

  • Current participation in aerobic exercise for ≥60 min/wk
  • Contraindication or impairment that precludes the potential participant from exercise as defined by the American College of Sports Medicine
  • The presence of serious medical illnesses, metal implants, previous brain trauma, epilepsy or history of seizures, previous surgery to the head or spinal cord, or skin problems at the forehead area where the tACS electrodes will be applied
  • Uncontrolled cardiovascular disease
  • Functional impairments or physical condition that would make exercise unsafe
  • Metastatic cancer or diagnosis of a different cancer (excluding melanoma) within the past 5 years
  • Contraindication to exercise a defined by the American College of Sports Medicine

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention Arm
The Exercise + transcranial alternating current stimulation (Ex+tACS) group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS. During tACS, 6Hz alternating current stimulation will be administered to participants' prefrontal cortex (forehead region) using a tACS while the participant completes the AX Continuous Performance Test (AX-CPT).
The Ex+tACS group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS while completing the AX Continuous Performance Test (AX-CPT).
Sham-komparator: Control
The Sham Comparator group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham transcranial alternating current stimulation (tACS) condition. The same procedures will be followed regarding the tACS, but stimulation will only last one minute, ramping up and down at the beginning and end of the 15-minute period, simulating the periodic tingling sensation that are reported with tACS.
The Control (CON) group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham tACS condition. After each session, both the EX+tACS and control participants will complete a questionnaire regarding experience with tACS.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adherence
Tidsramme: From baseline to the end of the 4-week intervention
Adherence will be calculated based on the percentage of prescribed sessions attended and percentage of participants who complete the prescribed exercise and tACS sessions.
From baseline to the end of the 4-week intervention
Retention
Tidsramme: From baseline to the end of the 4-week intervention
Retention will be determined by the number of enrolled breast cancer survivors who participate in the four-week intervention and complete post assessments.
From baseline to the end of the 4-week intervention
Acceptability
Tidsramme: From baseline to the end of the 4-week intervention
Acceptability will be determined by the percentage of participants who report satisfaction with the intervention.
From baseline to the end of the 4-week intervention
Safety (Adverse Events)
Tidsramme: From baseline to the end of the 4-week intervention
Safety (<5% of serious adverse events) will be determined by the percentage of participants experiencing a serious adverse event related to the program.
From baseline to the end of the 4-week intervention

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sustained attention
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in sustained attention, measured by performance on the AX-Continuous Performance Test (AX-CPT).
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Executive function
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in executive function, measured by performance (time) on the Trail Making Test Part A (TMT-A) and Part B (TMT-B).
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Inhibitory control
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in inhibitory control, measured by performance on the Flanker Compatibility Task.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Working Memory
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in working memory, measured by performance on the N-back and Backwards Counting tasks.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Subjective Cognition
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in subjective cognition, measured by the Functional Assessment Cancer Therapy-Cognition (FACT-COG)
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in lower body physical function, measured by the 30-second chair stand.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Cardiorespiratory endurance
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in cardiorespiratory fitness, measured by the six-minute walk test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Body fat percentage
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in body fat percentage measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Learning and Memory
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in learning and memory, assessed by the California Verbal Learning Test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Quality of Life (FACT-B)
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in quality of life, measured by the Functional Assessment of Cancer Therapy - Breast. Scores range from 0-148, with higher scores indicating better quality of life.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fatigue (FACIT-F)
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in fatigue, measured by the Functional Assessment of Chronic Illness Therapy-Fatigue. Scores range from 0-52, with higher scores indicating less fatigue.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Perceived exercise benefits and barriers
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in perceived benefits and barriers to exercise, measured by the Exercise Benefits/Barriers Scale (EBBS). Benefit scores range from 29-116, with higher scores indicating greater perceived benefits. Barrier scores range from 14-56, with higher scores indicating greater perceived barriers.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function (Short Physical Performance Battery)
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in physical function, assessed using the Short Physical Performance Battery. Scores range from 0-12, with higher scores indicating better physical function.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Muscle Power
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in lower body muscle power, measured by a single sit-to-stand using the Tendo Power Analyzer.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Grip strength
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in grip strength, measured using a hand-held grip strength dynamometer
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Upper body physical function
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in upper body physical function, measured by the 30-second arm curl test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fall Risk
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in fall risk, measured by the Falls Efficacy Scale. Scores range from 16-64, with higher scores indicating greater fall risk.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Activity
Tidsramme: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in physical activity, measured by an accelerometer.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Skeletal Muscle
Tidsramme: Baseline, within two weeks following the intervention, 4-week follow-up
Description: Researchers will assess pre- to post-intervention changes in skeletal muscle (kg) measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device
Baseline, within two weeks following the intervention, 4-week follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. januar 2026

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

30. januar 2026

Først indsendt, der opfyldte QC-kriterier

7. maj 2026

Først opslået (Faktiske)

14. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The dissemination plan includes sharing de-identified data for external researchers.

IPD-delingstidsramme

IPD will be available at the time of manuscript acceptance and publishing. A published manuscript is planned for 2027.

IPD-delingsadgangskriterier

Any external researcher will be able to access de-identified, non, PHI, individual participant data as part of the journal's supplementary information.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner